Novo Nordisk’s ambitious trial into whether its blockbuster obesity drug, semaglutide, could treat Alzheimer’s disease has been described as a "lottery ticket" by a senior executive, highlighting its uncertain yet potentially transformative prospects.
The Danish pharmaceutical giant anticipates receiving data from its crucial Alzheimer’s disease trial by the close of 2025.